UBS Oncology Impact Fund L.P. — SEC Form 4 filings
SEC reporting owner CIK 1691428. 11 Form 4 filings on record with FilingPulse; latest filed 2025-12-04.
Transaction summary — filings shown
Covers all 11 filings on record, filed 2025-04-30 to 2025-12-04. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 30 legs across 11 filings — 2,970,876 shares, $10,545,327 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 3.
- Largest priced transaction: sale of 1,031,931 shares @ $8.06 ($8,317,364) in iTeos Therapeutics, Inc., filed 2025-05-15.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| iTeos Therapeutics, Inc. (ITOS) | — | 1 | — | 1 leg · 1,031,931 sh · $8,317,364 | — |
| Werewolf Therapeutics, Inc. (HOWL) | — | 10 | — | 29 legs · 1,938,945 sh · $2,227,963 | 3 |
Form 4 filings — UBS Oncology Impact Fund L.P.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2025-12-04 | 4 | Werewolf Therapeutics, Inc. (HOWL) jointly with GADICKE ANSBERT, MPM ONCOLOGY INNOVATIONS FUND LP, Oncology Impact Fund (Cayman) Management L.P., MPM BioImpact LLC, MPM Oncology Innovations Fund GP LLC, MPM ASSET MANAGEMENT LLC | Sale (S): 59,277 @ $0.89 · Sale (S): 57,225 @ $0.87 · Sale (S): 83,230 @ $0.97 | EDGAR |
| 2025-12-01 | 4 | Werewolf Therapeutics, Inc. (HOWL) jointly with GADICKE ANSBERT, MPM ONCOLOGY INNOVATIONS FUND LP, Oncology Impact Fund (Cayman) Management L.P., MPM BioImpact LLC, MPM Oncology Innovations Fund GP LLC, MPM ASSET MANAGEMENT LLC | Sale (S): 60,733 @ $0.98 · Sale (S): 20,277 @ $0.99 · Sale (S): 60,917 @ $0.94 | EDGAR |
| 2025-11-25 | 4 | Werewolf Therapeutics, Inc. (HOWL) jointly with GADICKE ANSBERT, MPM ONCOLOGY INNOVATIONS FUND LP, Oncology Impact Fund (Cayman) Management L.P., MPM BioImpact LLC, MPM Oncology Innovations Fund GP LLC, MPM ASSET MANAGEMENT LLC | Sale (S): 64,331 @ $0.83 · Sale (S): 88,802 @ $0.98 · Sale (S): 42,533 @ $0.92 | EDGAR |
| 2025-11-20 | 4 | Werewolf Therapeutics, Inc. (HOWL) jointly with GADICKE ANSBERT, MPM ONCOLOGY INNOVATIONS FUND LP, Oncology Impact Fund (Cayman) Management L.P., MPM BioImpact LLC, MPM Oncology Innovations Fund GP LLC, MPM ASSET MANAGEMENT LLC | Sale (S): 52,627 @ $0.93 · Sale (S): 66,324 @ $0.94 · Sale (S): 41,152 @ $0.89 | EDGAR |
| 2025-11-17 | 4 | Werewolf Therapeutics, Inc. (HOWL) jointly with GADICKE ANSBERT, MPM ONCOLOGY INNOVATIONS FUND LP, Oncology Impact Fund (Cayman) Management L.P., MPM BioImpact LLC, MPM Oncology Innovations Fund GP LLC, MPM ASSET MANAGEMENT LLC | Sale (S): 90,951 @ $0.98 · Sale (S): 61,640 @ $0.93 · Sale (S): 57,061 @ $0.95 | EDGAR |
| 2025-11-12 | 4 | Werewolf Therapeutics, Inc. (HOWL) jointly with GADICKE ANSBERT, MPM ONCOLOGY INNOVATIONS FUND LP, Oncology Impact Fund (Cayman) Management L.P., MPM BioImpact LLC, MPM Oncology Innovations Fund GP LLC, MPM ASSET MANAGEMENT LLC | Sale (S): 68,480 @ $1.11 · Sale (S): 48,570 @ $1.18 · Sale (S): 55,810 @ $1.14 · Sale (S): 40,669 @ $1.09 | EDGAR |
| 2025-11-06 | 4 | Werewolf Therapeutics, Inc. (HOWL) jointly with GADICKE ANSBERT, MPM ONCOLOGY INNOVATIONS FUND LP, Oncology Impact Fund (Cayman) Management L.P., MPM BioImpact LLC, MPM Oncology Innovations Fund GP LLC, MPM ASSET MANAGEMENT LLC | Sale (S): 140,488 @ $1.22 · Sale (S): 47,950 @ $1.22 · Sale (S): 54,452 @ $1.21 | EDGAR |
| 2025-11-03 | 4 | Werewolf Therapeutics, Inc. (HOWL) jointly with GADICKE ANSBERT, MPM ONCOLOGY INNOVATIONS FUND LP, Oncology Impact Fund (Cayman) Management L.P., MPM BioImpact LLC, MPM Oncology Innovations Fund GP LLC, MPM ASSET MANAGEMENT LLC | Sale (S): 86,936 @ $1.43 · Sale (S): 114,044 @ $1.28 · Sale (S): 94,063 @ $1.29 | EDGAR |
| 2025-10-29 | 4 | Werewolf Therapeutics, Inc. (HOWL) jointly with GADICKE ANSBERT, MPM ONCOLOGY INNOVATIONS FUND LP, Oncology Impact Fund (Cayman) Management L.P., MPM BioImpact LLC, MPM Oncology Innovations Fund GP LLC, MPM ASSET MANAGEMENT LLC | Sale (S): 72,709 @ $1.72 · Sale (S): 69,068 @ $1.64 · Sale (S): 134,240 @ $1.55 | EDGAR |
| 2025-05-15 | 4 | iTeos Therapeutics, Inc. (ITOS) jointly with GADICKE ANSBERT, MPM BioImpact LLC, Oncology Impact Fund (Cayman) Management L.P. | Sale (S): 1,031,931 @ $8.06 | EDGAR |
| 2025-04-30 | 4 | Werewolf Therapeutics, Inc. (HOWL) jointly with GADICKE ANSBERT, MPM ONCOLOGY INNOVATIONS FUND LP, Oncology Impact Fund (Cayman) Management L.P., MPM BioImpact LLC, MPM Oncology Innovations Fund GP LLC, MPM ASSET MANAGEMENT LLC | Option exercise/expiry (X): 50,873 @ $0.09 · Sale (S): 4,386 @ $1.05 · Option exercise/expiry (X): 8,031 (derivative) @ $0 · Option exercise/expiry (X): 42,842 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1691428 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →